New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes ( MILAN Italy June 15 /CNW/

HOME >> MEDICINE >> TECHNOLOGY

New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes

MILAN, Italy, June 15 /CNW/ - Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from this study show that telmisartan reduces proteinuria to a significantly greater extent than losartan.(1)

Commenting on the results, Prof. Ellen Burgess, Foothills Hospital in Calgary, Canada said "The AMADEO results are encouraging for an increasing number of patients with type 2 diabetes because they suggest that telmisartan could improve renoprotection. It is particularly interesting that the observed effect was seen despite the study being controlled for blood pressure." She continued, "telmisartan has already shown superior blood pressure lowering compared to losartan and, in AMADEO, patients were allowed to take other medication, if needed, to ensure similar blood pressure in both treatment groups. This suggests that the protective benefits seen with telmisartan here are an additional attribute beyond its established blood pressure lowering effects."

Diabetic nephropathy is a kidney disease that occurs in approximately one third of patients with diabetes mellitus(2). These study results could, therefore, have a positive impact on millions of type 2 diabetes patients as well as healthcare systems worldwide. The prevalence of diabetes is projected to increase at an alarming rate from 171 million in 2000 to 366 million by 2030(3), with the upsurge in obesity closely linked to increased type 2 diabetes. Over time, diabetic nephropathy can lead to end-stage renal disease, a serious condition that needs dialysis and increased medical care and resources. End-stage renal disease has tripled in prevalence over the past two decades(4) and has huge associated healthcare costs, predicted to be US$28 billion by 2010 in the US alone(5).
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:

(Date:5/22/2013)... YORK , May 22, 2013 ... investigating potential claims on behalf of purchasers of ... the "Company") (NasdaqGS: AMAG -News). The investigation focuses ... federal securities laws. On May 22, ... during intraday trading after the company announced in ...

(Date:5/22/2013)... WHITE PLAINS, N.Y. , May 22, 2013 /PRNewswire/ ... $6 million to Valor Biotherapeutics, LLC, a ... completion of pre-clinical development, manufacturing, and a Phase I ... change the poor outcomes faced by many patients with ... with rituximab. Valor,s protein, IGN002, is ...

(Date:5/22/2013)... NEW YORK , May 22, 2013 The ... international conference devoted to advancing new treatments for lupus ... to 60 percent of patients. The conference launched a ... – the Lupus Nephritis Trials Network (LNTN). ... lupus and the kidney came together to focus on ...

Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4 Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2

[0] Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.[0] The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients [0] Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis

... N.J., Sept. 29 Sparta Systems, Inc. ... software and the market leader in enterprise ... Qualitest Pharmaceuticals , a top-six provider of ... streamline multiple quality and compliance processes. ...

... China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...

Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010

(Date:5/22/2013)... Researchers in genomic health disparities from the University ... University School of Medicine have teamed up to hold ... Eliminate Health Disparities in Genomic Medicine." The theme ... nonprofits, business and government to reduce these disparities. , ... United States, individuals within underserved groups continue to be ...

(Date:5/22/2013)... By Maureen Salamon HealthDay Reporter , , WEDNESDAY, ... each cause a great deal of suffering, but new ... linked to something else entirely -- a smaller brain. ... double the risk of depression, scientists wanted to determine ... The difference in size -- about 2 percent -- ...

(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...

(Date:5/22/2013)... May 22, 2013 Recent tragedies ... and the school shooting in Newtown, Connecticut all ... , Emergency medical practitioners train to ... the Emergency Medical Services for Children (EMSC) Program ... care for the youngest patients. It is estimated ...

(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science ... sharing a recipe for making energy bars at home. , ... ,” takes a recipe modified from one recently featured ... day it gets more and more difficult to understand what ... size of the nutrition label continues to grow and consumers ...

Breaking Medicine News(10 mins):Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 3 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3 Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2 Health News:How To "Make Your Own Healthy Energy Bars" 2

[0] Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine [0] Having Both Migraines, Depression May Mean Smaller Brain [0] Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year”[0] When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care [0] How To "Make Your Own Healthy Energy Bars"

... World Health Organization expected to make recommendation next week, ... Vaccine manufacturers and other health experts met Thursday at ... plot potential strategies to combat the swine flu virus ... infection worldwide. , The Associated Press reported ...

... In conjunction with CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, ... Internet on Thursday, June 4th at 11:30 am Eastern Time., Event: ... Hosted by: Dan Starck, President and CEO, ... Chairman, Date: 11:30 am ...

... OAK BROOK, Ill. May 14, 2009 In ... Barrett,s esophagus, electronic diagnosis overestimated the prevalence of the ... only 61.9 percent of patients assigned a billing diagnosis ... a manual record review. The study evaluated the accuracy ...

... country join forces to advocate for more research funding ... we continue to mark Food Allergy Awareness Week, Robert ... of the Food Allergy Initiative (FAI), announced the formation ... are to help build a strong nationwide presence for ...

... May 14 If the H1N1 pandemic flu follows the ... with more vigor in a second wave next fall. In ... unusual rapidity, resulting in 3 explosive pandemic waves within a ... for the Prudent Use of Antibiotics and Microbiology Lab Director ...

... of life over 8 years of follow-up, study finds, ... (ICDs) extend heart patients, lives even eight years after ... be presented Thursday at the Heart Rhythm Society annual ... ICD therapy, sustained for over eight years, does in ...

Health Experts Plot Strategy for Swine Flu Vaccine CorVel Announces Fiscal Year Earnings Release Webcast Study examines reliability of clinical and pathological diagnoses of Barrett's esophagus Robert F. Kennedy, Jr. Announces New Food Allergy Initiative Advocacy Steering Committee H1N1 Pandemic Precautions for Front Line Workers Implanted Defibrillators Boost Long-Term Survival

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

Medicine Products:

Doxepin, Urine Drinox, Serum Dramamine, Urine Doxycycline, Antimicrobial (Serum or Body Fluid) Level, BA